SCHEMBL26547744

SCHEMBL26547744

COc1cc(N2CCOCC2)cc2c1cc(C)c(=O)n2C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.45
PDE2A O00408 5/20 0.42
PDE10A Q9Y233 5/20 0.42
PDE6D O43924 3/20 0.42
PDE6A P16499 3/20 0.42
PDE6G P18545 3/20 0.42
PDE6B P35913 3/20 0.42
PDE6C P51160 3/20 0.42
PDE6H Q13956 3/20 0.42
PDE4A P27815 2/20 0.42
PDE4B Q07343 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 3/20 0.41
THRB P10828 2/20 0.41
POLB P06746 2/20 0.41
HPGD P15428 1/20 0.41
P2RY12 Q9H244 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30480887 1.00 PIK3CA (0.45) PIK3CAPDE2APDE10APDE6DPDE6A
SCHEMBL30480903 0.82 KDM4E (0.34) PIK3CAPDE2APDE10AALDH1A1POLB
SCHEMBL26547751 0.82 KDM4E (0.34) PIK3CAPDE2APDE10AALDH1A1POLB
SCHEMBL30480878 0.82 PRKDC (0.44) PIK3CAMEN1ALDH1A1KMT2AHPGD
SCHEMBL26547748 0.82 PRKDC (0.44) PIK3CAMEN1ALDH1A1KMT2AHPGD
SCHEMBL29471279 0.78 BRD4 (0.41) ALDH1A1POLBBRPF1EHMT2EHMT1
SCHEMBL26111817 0.78 BRD4 (0.41) ALDH1A1POLBBRPF1EHMT2EHMT1
SCHEMBL31496296 0.77 ALDH1A1 (0.42) MEN1ALDH1A1KMT2AKDM4EMAPT
SCHEMBL31426266 0.76 TNFRSF1A (0.33) MEN1ALDH1A1KMT2AP2RY12BRPF1
SCHEMBL31425838 0.76 ALOX5 (0.37) MEN1KMT2ABRD4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 PIK3CA 1790/4885PDE2A 2584/4885PDE10A 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.